Corpus Intelligence IC Memo — HILLCREST MEDICAL CENTER 2026-04-26 03:58 UTC
IC Memo — HILLCREST MEDICAL CENTER
Investment Committee Memorandum | OK | 424 beds | Grade C | EBITDA uplift $43.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HILLCREST MEDICAL CENTER

CCN 370001 | TULSA, OK | 424 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HILLCREST MEDICAL CENTER is a 424-bed safety-net/medicaid heavy in TULSA, OK with $590.1M in net patient revenue and a -3.3% operating margin. The hospital serves a payer mix of 21.4% Medicare, 33.2% Medicaid, and 45.3% commercial.

Thesis: Undervalued. Our ML models identify $43.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -3.3% to 4.0% (+736bps).

Net Revenue HCRIS$590.1M
Current EBITDA COMPUTED$-19.6M
Operating Margin COMPUTED-3.3%
Occupancy HCRIS75.6%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS13.7%
Distress Probability ML48.2%

2. Market Context & Competitive Position

147
OK Hospitals
-8.8%
State Median Margin
1100
Comparable Hospitals

OK has 147 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -3.3% places it above the state median. Among 1100 size-comparable peers (212-848 beds), the median margin is -3.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (212-848), prioritizing same-state peers. 1100 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HILLCREST MEDICAL CENTER (Target)OK424$590.1M-3.3%
ST. LUKES HOSPITALPA633$8.94B87.9%
STANFORD HEALTH CARECA657$6.76B3.7%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
STRONG MEMORIAL HOSPITALNY749$3.31B5.2%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
UCSD MEDICAL CENTERCA718$3.06B-7.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $43.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$12.4M+210bp18mo
Cost to Collect4.5%2.5%$11.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$11.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$7.2M+122bp9mo
Clean Claim Rate88.0%96.0%$378K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$12.4M
Cost to Collect
$11.8M
Denial Rate Reduction
$11.7M
A/R Days Reduction
$7.2M
Clean Claim Rate
$378K
Total EBITDA Uplift$43.4M
Current EBITDA$-19.6M
+ RCM Uplift+$43.4M
Pro Forma EBITDA$23.8M
Current Margin-3.3%
Pro Forma Margin4.0%
WC Released (1x)$22.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-30.2M$305.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-30.2M$325.7M0.00x-100.0%
Bull Case9.0x11.0x$-27.2M$459.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-27.2M$492.9M0.00x-100.0%
Bear Case11.0x10.0x$-33.2M$97.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-33.2M$96.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (33.2%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 1100 hospitals with 212-848 beds
  • Same-state prioritization (n=8)
  • Comp margins: P25=-13.5% / P50=-3.8% / P75=5.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.